Disc Medicine (NASDAQ:IRON) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Disc Medicine (NASDAQ:IRON - Free Report) in a research note published on Wednesday morning, MarketBeat.com reports. The firm issued a buy rating and a $89.00 price objective on the stock.

A number of other research analysts have also recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and set a $70.00 price objective on shares of Disc Medicine in a research report on Monday, September 16th. Scotiabank initiated coverage on shares of Disc Medicine in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $62.00 price objective for the company. Cantor Fitzgerald reissued an "overweight" rating and set a $85.00 price target on shares of Disc Medicine in a research report on Tuesday, October 15th. Wells Fargo & Company started coverage on shares of Disc Medicine in a research report on Thursday, August 22nd. They issued an "overweight" rating and a $75.00 price objective for the company. Finally, Wedbush reiterated an "outperform" rating and issued a $57.00 price target on shares of Disc Medicine in a report on Friday, August 9th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, Disc Medicine currently has a consensus rating of "Moderate Buy" and a consensus price target of $66.40.

Disc Medicine Price Performance

IRON stock traded down $3.93 during trading on Wednesday, hitting $46.99. 397,234 shares of the stock traded hands, compared to its average volume of 346,424. The firm's 50 day moving average is $48.98 and its two-hundred day moving average is $41.90. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -13.92 and a beta of 0.59. Disc Medicine has a 1 year low of $25.60 and a 1 year high of $77.60.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, topping analysts' consensus estimates of ($1.11) by $0.08. As a group, analysts anticipate that Disc Medicine will post -4.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Disc Medicine

Several large investors have recently modified their holdings of the stock. Amalgamated Bank increased its position in Disc Medicine by 76.9% during the 2nd quarter. Amalgamated Bank now owns 568 shares of the company's stock worth $26,000 after purchasing an additional 247 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Disc Medicine by 19.5% during the 3rd quarter. SG Americas Securities LLC now owns 4,864 shares of the company's stock valued at $239,000 after buying an additional 793 shares during the period. Bleakley Financial Group LLC raised its holdings in shares of Disc Medicine by 23.0% during the 1st quarter. Bleakley Financial Group LLC now owns 4,572 shares of the company's stock valued at $285,000 after buying an additional 856 shares during the period. TD Asset Management Inc raised its holdings in shares of Disc Medicine by 3.7% during the 2nd quarter. TD Asset Management Inc now owns 40,732 shares of the company's stock valued at $1,836,000 after buying an additional 1,468 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Disc Medicine during the 2nd quarter valued at about $129,000. Hedge funds and other institutional investors own 83.70% of the company's stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.